Atypical Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Welcome to the PKAN Road Map

Looking for the PKAN My Med Team Social Network?

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

FDA Approves Radicava (edaravone) to Treat ALS

Regenerative Neurobiology

ALS Treatment Updates

  • BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22 16 Jan 2018 11:39 Kait Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please …
  • Felony charges filed in regards to 2014 sale of missing York County man’s home 20 Dec 2017 23:02 WPMT Please enable Javascript to watch this video DOVER TOWNSHIP, YORK COUNTY -- New developments are being revealed surrounding the disappearance of a York County man. It's been around a decade since Thomas Hayden's family members last spoke with him, …
  • First step toward CRISPR cure of Lou Gehrig’s disease 20 Dec 2017 19:38 UC Berkeley NewsCenter University of California, Berkeley scientists have for the first time used CRISPR-Cas9 gene editing to disable a defective gene that causes amyotrophic lateral sclerosis, or Lou Gehrig’s disease, in mice, extending their lifespan by 25 percent. Diagram of …
  • Bizzare story of a disappearance of a York County man leads to charges against Texas woman, leaves questions unanswered 19 Dec 2017 17:40 WPMT × Bizzare story of a disappearance of a York County man leads to charges against Texas woman, leaves questions unanswered YORK COUNTY, Pa.– A bizzare story has led to a Texas woman facing charges after allegedly tampering with public information and …
  • New ALS Treatment Offer Hope by Infusion 28 Nov 2017 20:56 KMOX ST. LOUIS (KMOX) – Local ALS patients and their doctors welcome the first new drug to treat the disease in more than 20 years. It’s called Radicava, a near-daily infusion treatment that helps slow progression of the degenerative disease better known as …
  • Cytokinetics Pivots to Another ALS Drug After Phase 3 Failure 21 Nov 2017 21:55 Xconomy Xconomy San Francisco —  Cytokinetics’ bid to offer a new drug for amyotrophic lateral sclerosis (ALS) was dealt a setback after the company’s lead experimental treatment for the disease failed in a late-stage clinical trial. The results mean the end for …
  • Mid-Afternoon Market Update: Dow Gains 180 Points; DSW Shares Drop On Earnings Miss 21 Nov 2017 20:12 Benzinga Toward the end of trading Tuesday, the Dow traded up 0.77 percent to 23,611.66 while the NASDAQ climbed 0.95 percent to 6,855.20. The S&P also rose, gaining 0.67 percent to 2,599.38. Leading and Lagging Sectors Tuesday afternoon, the technology sector …
  • Mid-Day Market Update: Signet Jewelers Falls After Q3 Results; Cheetah Mobile Shares Surge 21 Nov 2017 18:09 Benzinga Midway through trading Tuesday, the Dow traded up 0.73 percent to 23,600.44 while the NASDAQ climbed 0.97 percent to 6,856.47. The S&P also rose, gaining 0.63 percent to 2,598.40. Leading and Lagging Sectors On Tuesday, the technology sector proved to …
  • A treatment for ALS just failed a key clinical trial 21 Nov 2017 16:48 Business Insider Cytokinetics said Tuesday that its treatment for ALS failed in a late-stage clinical trial.  Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a fatal neuro-degenerative condition that affects nerve cells in the brain and the spinal cord. …
  • Why Is Cytokinetics Plunging Today? 21 Nov 2017 15:20 Benzinga Cytokinetics, Inc. (NASDAQ: CYTK) shares are plunging in pre-market trading Tuesday on the back of negative trial results for its amyotrophic lateral sclerosis, or ALS, treatment candidate tirasemtiv in a late-stage study. The results of the international …

 

Showing listings 1-9 of 4328

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

ALS Groups

 

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

Featured

View all

PKAN Updates

  • Top three posts should be shared, says PKAN 23 Jan 2018 14:53 Daily Express Top three posts should be shared, says PKAN Published on: Tuesday, January 23, 2018 Kota Kinabalu: "All Sabahans especially the Momogun, Bajau Suluk/ Brunei and Chinese must unite and fight together as Anak Negeri and exert our rights under the …
  • ArTara Therapeutics Announces Addition of Randall Marshall, MD as Chief Medical Officer 09 Jan 2018 03:26 MarketWatch.com NEW YORK, Jan 08, 2018 (BUSINESS WIRE) -- ArTara today announces the appointment of Randall Marshall, MD as Chief Medical Officer and President of Research & Development. Dr. Marshall will join as a co-founder of ArTara to provide scientific and …
  • Retrophin's (RTRX) CEO Steve Aselage on Q3 2017 Results - Earnings Call Transcript 11 Nov 2017 12:31 Seeking Alpha Retrophin, Inc. (NASDAQ:RTRX) Q3 2017 Earnings Conference Call November 7, 2017 04:30 PM ET Executives Chris Cline - IR Steve Aselage - CEO Neil McFarlane - COO Laura Clague - CFO Bill Rote - SVP and Head of Research and Development Analysts Dae Gon - …
  • TM3 Therapeutics Debuts with Publication of In Vivo Proof of Concept Data for Lead Compound in Treating Pantothenate Kinase-Associated Neurodegeneration 13 Sep 2017 09:02 PharmiWeb.com TM3 Therapeutics Posted on: 13 Sep 17 TM3 Therapeutics, a biopharmaceutical company focused on developing metabolite replacement therapies for rare, genetic neurological diseases, today announced the publication of novel preclinical data on its lead …
  • Retrophin to Present at September Investor Conferences 11 Sep 2017 20:41 MarketWatch.com SAN DIEGO, Sep 11, 2017 (GLOBE NEWSWIRE via COMTEX) -- Retrophin, Inc. RTRX, +0.25% today announced that Stephen Aselage, chief executive officer, will present at two upcoming investor conferences in New York City, including: Cantor Fitzgerald Global …
  • Clinical trial in St. Louis could save local girl’s life 26 Aug 2017 01:50 KTVI Please enable Javascript to watch this video ST. LOUIS – Annaliese Hupp suffers from a debilitating neurodegenerative disorder known simply as PKAN. The 8-year-old relies on a ventilator to help her breath and her parents care 24 hours a day. Her body has …
  • Retrophin Inc Has Returned 28.1% Since SmarTrend Recommendation (RTRX) 22 Aug 2017 05:38 Tradingcharts.com Aug 21, 2017 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Retrophin Inc (NASDAQ:RTRX) on June 19th, 2017 at $18.41. In approximately 2 months, Retrophin Inc has returned 28.14% as of today's recent price of $23.59. In the …
  • Retrophin: Updates To Thesis 21 Aug 2017 18:42 Seeking Alpha Shares of Retrophin (NASDAQ:RTRX) have climbed by around 50% since I first started covering the company. Year to date, the share price has risen by nearly 25%. Key elements of the bull thesis in my most recent entry included the following: An $800 million …
  • Grandmother opens up about grandson's terminal illness 14 Aug 2017 22:54 Charleston Daily Mail Erin Heasley started noticing something was wrong with her son, Riley, when he was only nine months old in 2009. He was not developing at the same rate as other babies his age in Longmont, Colorado. He started sitting up far later than he should have done …
  • Ride for Riley to benefit research into Longmont boy's rare disease 13 Aug 2017 16:59 The Daily Camera If you go What: Ride for Riley When: 10 a.m. Saturday Where: Starts at Garden Gate Cafe, 7960 Niwot Road Cost: $25 per vehicle and $10 per additional poker tally card More info: bit.ly/2uwzbLU A Longmont family is hoping to put a dent in a $2 million …
  • Retrophin's (RTRX) CEO Steve Aselage on Q2 2017 Results - Earnings Call Transcript 11 Aug 2017 20:25 Seeking Alpha Retrophin, Inc. (NASDAQ:RTRX) Q2 2017 Earnings Conference Call August 9, 2017 4:30 PM ET Executives Chris Cline – Vice President-Investor Relations Steve Aselage – Chief Executive Officer Bill Rote – Senior Vice President and Head-Research and Development …
  • Buy vet and pet crematoria firm CVS 25 Jun 2017 16:17 Daily Mail We round up the Sunday newspaper share tips. This week, Midas looks at vet chain CVS Group and middle class clothing brand Joules, while the Sunday Telegraph analyses Royal Mail.  The Sunday Times meanwhile delves into why The Lady from the Provvy has …
  • Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued Patents in the United States and Europe 01 Jun 2017 12:23 GlobeNewswire SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have each issued a patent covering the Company’s product candidate …
  • The Investment Case For Retrophin 05 May 2017 16:57 Seeking Alpha Retrophin (NASDAQ:RTRX) is trading at an enterprise value of around $450 million while having three marketed products and what looks like a solid pipeline and a robust balance sheet that allows the company to pursue additional deals. I avoided Retrophin …
  • Retrophin's (RTRX) CEO Steve Aselage on Q1 2017 Results - Earnings Call Transcript 05 May 2017 00:32 Seeking Alpha Retrophin, Inc. (NASDAQ:RTRX) Q1 2017 Earnings Conference Call May 4, 2017 4:30 p.m. ET Executives Chris Cline - VP, IR Steve Aselage - CEO Neil McFarlane - COO Laura Clague - CFO Bill Rote - SVP, and Head of R&D Analysts Tim Lugo - William Blair Do …
  • Retrophin Reports First Quarter 2017 Financial Results 04 May 2017 20:09 GlobeNewswire Phase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017 Protocol development underway for pivotal Phase 3 trial of sparsentan in FSGS First quarter revenues rose 16 percent to $34 million SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. ( …
  • Retrophin to Report First Quarter 2017 Financial Results 20 Apr 2017 20:38 GlobeNewswire April 20, 2017 16:30 ET | Source: Retrophin, Inc. SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017 after the close of the U.S. …
  • Retrophin Appoints Ron Squarer to Board of Directors 12 Apr 2017 20:35 GlobeNewswire SAN DIEGO, April 12, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Ron Squarer to the Company’s Board of Directors, effective immediately. Mr. Squarer is chief executive officer and a director of Array BioPharma …
  • John A. Orwin Joins Retrophin Board of Directors 23 Mar 2017 21:32 GlobeNewswire SAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of John A. Orwin to the Company’s Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of Relypsa, Inc …
  • NephCure Kidney International® Launches the NephCure Accelerating Cures Institute® 21 Mar 2017 12:11 Kait Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please …

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

[google_news query=’als’ topic=snc topic=t topic=b topic=s topic=m]

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2017 My City Med. All Rights Reserved.

or

Log in with your credentials

or    

Forgot your details?

or

Create Account

Skip to toolbar